Association of Comorbidities With Overall Survival in Myelodysplastic Syndrome: Development of a Prognostic Model
- 1 June 2011
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 29 (16), 2240-2246
- https://doi.org/10.1200/jco.2010.31.3353
Abstract
Patients with cancer often experience comorbidities that may affect their prognosis and outcome. The objective of this study was to determine the effect of comorbidities on the survival of patients with myelodysplastic syndrome (MDS). We conducted a retrospective cohort study of 600 consecutive patients with MDS who presented to MD Anderson Cancer Center from January 2002 to December 2004. The Adult Comorbidity Evaluation-27 (ACE-27) scale was used to assess comorbidities. Data on demographics, International Prognostic Scoring System (IPSS), treatment, and outcome (leukemic transformation and survival) were collected. Kaplan-Meier methods and Cox regression were used to assess survival. A prognostic model incorporating baseline comorbidities with age and IPSS was developed to predict survival. Overall median survival was 18.6 months. According to the ACE-27 categories, median survival was 31.8, 16.8, 15.2, and 9.7 months for those with none, mild, moderate, and severe comorbidities, respectively (P < .001). Adjusted hazard ratios were 1.3, 1.6, and 2.3 for mild, moderate, and severe comorbidities, respectively, compared with no comorbidities (P < .001). A final pognostic model including age, IPSS, and comorbidity score predicted median survival of 43.0, 23.0, and 9.0 months for lower-, intermediate-, and high-risk groups, respectively (P < .001). Comorbidities have a significant impact on the survival of patients with MDS. Patients with severe comorbidity had a 50% decrease in survival, independent of age and IPSS risk group. A comprehensive assessment of the severity of comorbidities helps predict survival in patients with MDS.Keywords
This publication has 33 references indexed in Scilit:
- Cause of death in patients with lower‐risk myelodysplastic syndromeCancer, 2010
- Comorbidities and survival in a large cohort of patients with newly diagnosed myelodysplastic syndromesLeukemia Research, 2009
- Clinical relevance of extra-hematologic comorbidity in the management of patients with myelodysplastic syndromeHaematologica, 2009
- Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring SystemCancer, 2008
- A prognostic score for patients with lower risk myelodysplastic syndromeLeukemia, 2007
- Myelodysplastic syndromes, aging, and age: Correlations, common mechanisms, and clinical implicationsLeukemia & Lymphoma, 2007
- The Impact Of Co-morbid Disease on Cancer Control and Survival Following Radical CystectomyJournal of Urology, 2003
- A new clinical-anatomic staging system for evaluating prognosis and treatment of prostatic cancerJournal of Chronic Diseases, 1986
- The importance of classifying initial co-morbidity in evaluating the outcome of diabetes mellitusJournal of Chronic Diseases, 1974
- The pre-therapeutic classification of co-morbidity in chronic diseaseJournal of Chronic Diseases, 1970